April 4, 2024: ICD-Pieces Trial Sees No Reduction in Hospitalization for Patients With Chronic Kidney Disease

Dr. Miguel Vazquez, principal investigator for ICD-Pieces

A primary care intervention for patients with coexisting chronic kidney disease, type 2 diabetes, and hypertension did not reduce the hospitalization rate for these patients when compared to usual care, according to the ICD-Pieces study.

The results of the study were published this week in the New England Journal of Medicine.

ICD-Pieces, an NIH Collaboratory Trial, was a cluster randomized, pragmatic clinical trial testing an intervention that used an electronic health record–based algorithm and practice facilitators in 141 primary care practices. The study team randomly assigned more than 11,000 adults to receive either the intervention or usual care. The large, diverse study population—of whom 20% were Black and almost 20% were Hispanic or Latino—was representative of the population with chronic kidney disease, type 2 diabetes, and hypertension in the United States.

In the intervention group, the study team used an algorithm to identify patients in the electronic health record in real time. Practice facilitators then worked with the participating primary care providers and patients to meet blood pressure targets, promote use of appropriate medications, achieve goals for blood glucose control, and engage in other guideline-directed care. The intervention period lasted 12 months, and the primary outcome was hospitalization for any reason.

At the end of the study, the hospitalization rate was similar between the intervention group and the usual care group. Rates of key secondary outcomes, such as emergency department visits and cardiovascular events, were also similar between the groups.

Read the full article.

“Although we did not observe a difference in the primary outcome, we believe the study is an important step in advancing our understanding of how to conduct pragmatic trials embedded in healthcare systems,” said Dr. Miguel Vazquez, the principal investigator for ICD-Pieces and a professor of internal medicine at UT Southwestern Medical Center in Dallas.

The study team identified and enrolled a large number of patients, including a large proportion of patients who are members of racial and ethnic groups that are usually underrepresented in clinical trials, Vazquez explained. Moreover, the intervention was delivered across 4 large healthcare systems using a variety of electronic health record systems, there was fidelity in intervention delivery, and there was robust capture of outcomes in a diverse population with multiple chronic conditions.

Vazquez also emphasized the value of conducting the ICD-Pieces study as an NIH Collaboratory Trial.

“The opportunity to work within the NIH Pragmatic Trials Collaboratory was essential for the successful completion of our trial,” Vazquez said. “Access to the expertise from the Coordinating Center and ongoing interactions with investigators from other projects provided critical knowledge to conduct our study embedded in large health systems,” he added.

ICD-Pieces is supported within the NIH Pragmatic Trials Collaboratory by a cooperative agreement from the National Institute of Diabetes and Digestive and Kidney Diseases.

Learn more about ICD-Pieces.

March 27, 2024: A Cluster Randomized Trial to Improve Kidney Transplant Access, in This Week’s PCT Grand Rounds

Drs. Amit Garg and Stephanie Dixon

In this Friday’s PCT Grand Rounds, Amit Garg and Stephanie Dixon of Western University’s Schulich School of Medicine and Dentistry will present “Effect of a Multicomponent Intervention to Improve Patient Access to Kidney Transplant and Living Kidney Donation: A Pragmatic, Cluster-Randomized Trial.”

The Grand Rounds session will be held on Friday, March 27, 2024, at 1:00 pm eastern.

Garg is the associate dean for clinical research at the Schulich School of Medicine and Dentistry and the lead of the provincial Kidney, Dialysis and Transplantation Program of the Institute for Clinical Evaluative Sciences (ICES KDT). Dixon is a biostatistician at the London Health Sciences Centre and the program manager for ICES KDT.

Join the online meeting.

January 3, 2024: Special Biostatistics Series Concludes With Missing Data in Cluster Randomized Trials

In this Friday's PCT Grand Rounds, Rui Wang of Harvard Medical School will offer the final session in our special series, Advances in the Design and Analysis of Pragmatic Clinical Trials, with "Methods for Handling Missing Data in Cluster Randomized Trials." The session will be held on Friday, January 5, at 1:00 pm eastern.

Wang is an associate professor of population medicine and the director of the Division of Biostatistics in the Department of Population Medicine at Harvard Medical School and the Harvard Pilgrim Health Care Institute. She is also an associate professor in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health. She is a longtime member of the NIH Pragmatic Trials Collaboratory's Biostatistics and Study Design Core Working Group.

This session's moderator, Fan Li, is an assistant professor of biostatistics at the Yale School of Public Health.

Join the online meeting.

This special Grand Rounds series includes moderated webinar discussions that bring together biostatisticians, clinical trials methodologists, and investigators to discuss challenges and share lessons learned in the design, implementation, and analysis of pragmatic trials. Download the series flyer and see the full schedule below, including archived webinar recordings and slides from previous sessions.

All sessions are free and open to the public. No registration is required.

November 1, 2023: Special Biostatistics Series Continues With Complex Clustering in Pragmatic Trials

In this Friday’s PCT Grand Rounds, Jonathan Moyer of the NIH Office of Disease Prevention will continue our special series, Advances in the Design and Analysis of Pragmatic Clinical Trials, with his presentation, “The Perils and Pitfalls of Complex Clustering in Pragmatic Trials.” The session will be held on Friday, November 3, at 1:00 pm eastern and will be moderated by Andrea Cook.

Moyer is a statistician in the NIH Office of Disease Prevention. He is a longtime member of the NIH Pragmatic Trials Collaboratory’s Biostatistics and Study Design Core. This session’s moderator, Andrea Cook, is a senior biostatistics investigator in the Kaiser Permanente Washington Health Research Institute.

Join the online meeting.

This special Grand Rounds series will include additional moderated webinar discussions that bring together biostatisticians, clinical trials methodologists, and investigators to discuss challenges and share lessons learned in the design, implementation, and analysis of pragmatic trials. Download the series flyer and see the full schedule below.

All sessions are free and open to the public; no registration is required.

September 5, 2023: NIH Pragmatic Trials Collaboratory Announces Grand Rounds Series on Design and Analysis of Pragmatic Clinical Trials

Promotional graphic showing details of the upcoming sessions of special Grand Rounds series, "Advances in the Design and Analysis of Pragmatic Clinical Trials"The NIH Pragmatic Trials Collaboratory is launching a special Grand Rounds series to share advances in the design and analysis of pragmatic clinical trials.

Join us on the first Friday of each month, October through January, to hear the latest best practices and explore emerging questions with experts from the program’s Biostatistics and Study Design Core.

Over the past decade, the Core has worked with investigators to fine-tune study designs, develop rigorous analysis plans, and offer guidance to the broader community of researchers who are planning pragmatic trials. With this new Grand Rounds series, the Core is bringing together biostatisticians, clinical trials methodologists, and investigators to discuss challenges and share lessons learned in the design, implementation, and analysis of pragmatic trials.

The webinar series, Advances in the Design and Analysis of Pragmatic Clinical Trials, will kick off on Friday, October 6, at 1:00 pm ET with a presentation on design and analysis considerations for implementation trials by David Murray, NIH associate director for disease prevention and director of the NIH Office of Disease Prevention.

The series will include 3 additional moderated webinar discussions. These sessions will focus on a range of topics, including complex clustering, best practices in the design and analysis of stepped-wedge trials, and handling missing data in cluster randomized trials.

Download the series flyer and see the full schedule below:

All sessions are free and open to the public; no registration is required. Recordings will be archived on the Rethinking Clinical Trials website.

June 14, 2023: IMPACt-LBP and INSPIRE Have Updated Study Snapshots, Ethics and Regulatory Documentation

Updated study snapshots and ethics and regulatory documentation are now available for the IMPACt-LBP and INSPIRE trials, both NIH Pragmatic Trials Collaboratory Trials.

Logo for the IMPACt-LBP NIH Collaboratory TrialIMPACt-LBP transitioned from the planning phase to the implementation phase in August. As part of the transition, the study team reviewed and updated the minutes of their initial consultation with the Ethics and Regulatory Core. The study is a cluster randomized trial evaluating the effect of first-contact patient referral to physical therapists and doctors of chiropractic for the treatment of low back pain. IMPACt-LBP is supported within the NIH Collaboratory under an award from the National Center for Complementary and Integrative Health.

Logo for the INSPIRE NIH Collaboratory TrialINSPIRE joined the NIH Collaboratory at the beginning of its implementation phase. The study team held its initial consultation with the Ethics Regulatory Core to review their approach their approach to consent, data privacy, and the applicability of recent FDA guidance regarding clinical decision support software functions. INSPIRE consists of 2 cluster randomized trials that are using personalized clinical decision support to improve judicious antibiotic prescribing for non–critically ill patients hospitalized with abdominal infections or skin and soft tissue infections. The project is supported within the NIH Collaboratory under an award from the National Institute of Allergy and Infectious Diseases.

May 15, 2023: EMBED Offers Lessons for Intervention Adoption, Implementation, and Maintenance

EMBED logoOrganizational culture, clinician training and support, the ability to link patients to ongoing treatment, and the ability to tailor implementation to each clinical site were key determinants of successful implementation of an intervention to promote buprenorphine initiation in emergency departments, according to a qualitative study conducted as part of the EMBED pragmatic clinical trial.

The study’s findings were published recently in Implementation Science Communications.

EMBED, an NIH Collaboratory Trial, was a cluster randomized trial across 21 emergency departments in 5 healthcare systems in the United States. The trial tested the effectiveness of a clinical decision support tool integrated into the electronic health record in improving rates of buprenorphine initiation in the emergency department for the treatment of opioid use disorder. The intervention led to a modest increase in buprenorphine initiation and little impact on patient outcomes.

A secondary aim of the study was to identify determinants of adopting, implementing, and maintaining the clinical decision support tool at the trial sites. Among the key determinants were:

  • establishing buprenorphine initiation as a cultural norm within healthcare organizations;
  • organizational commitment to implementing and sustaining the intervention;
  • clinician training and support on opioid use disorder and buprenorphine initiation in emergency departments;
  • availability of referral resources to link patients who were initiated on buprenorphine in the emergency to ongoing treatment; and
  • the ability to tailor the intervention to clinic workflows that fit the resources and characteristics of the local clinic.

EMBED was supported within the NIH Collaboratory by a cooperative agreement from the National Institute on Drug Abuse and received logistical and technical support from the NIH Collaboratory Coordinating Center. Read more about EMBED in the Living Textbook, and learn about the other NIH Collaboratory Trials.

Read the full report.

April 26, 2023: In This Week’s PCT Grand Rounds, a Cluster-Crossover Trial of Oxygen Saturation Targets

Headshot of Dr. Matthew SemlerIn this Friday’s PCT Grand Rounds, Matthew Semler of Vanderbilt University will present “Oxygen-Saturation Targets for Critically Ill Adults Receiving Mechanical Ventilation: An Embedded Cluster-Crossover Trial.” The Grand Rounds session will be held on Friday, April 28, 2023, at 1:00 pm eastern.

Dr. Semler is an assistant professor of medicine and bioinformatics and the medical director of the Center for Learning Healthcare in the Vanderbilt Center for Clinical and Translational Research.

Join the online meeting.

April 19, 2023: MyTEMP Cluster Randomized Trial to Be Featured in This Week’s PCT Grand Rounds

Headshot of Dr. Amit GargIn this Friday’s PCT Grand Rounds, Amit Garg and Stephanie Dixon of Western University’s Schulich School of Medicine & Dentistry will present “Personalised Cooler Dialysate for Patients Receiving Maintenance Haemodialysis (MyTEMP): A Pragmatic, Cluster-Randomised Trial.” The Grand Rounds session will be held on Friday, April 21, 2023, at 1:00 pm eastern.

Dr. Garg is a professor of medicine, epidemiology, and biostatistics and the associate dean for clinical research in the Schulich School of Medicine & Dentistry. The MyTEMP trial is the first large, randomized trial to assess the effects of cooler dialysis fluid temperature on patient outcomes.

Join the online meeting.

March 15, 2023: IMPACt-LBP Enrolls First Patient in Study of Collaborative Care for Low Back Pain

IMPACt-LBP, an NIH Pragmatic Trials Collaboratory Trial, enrolled its first study participant this week. Congratulations to the IMPACt-LBP study team for reaching this important project milestone!

IMPACt-LBP investigators
Dr. Christine Goertz, Dr. Adam Goode, Dr. Jon Lurie, and Dr. Rishi Chakraborty

Co-led by investigators at Duke University and Dartmouth University, IMPACt-LBP is a cluster randomized trial of a multidisciplinary collaborative team approach for low back pain versus usual care. In the intervention arm, patients with a primary complaint of low back pain are referred to physical therapists and chiropractic doctors as first-line providers. The study will determine whether receiving first-line care from these “primary spine practitioners” improves physical function, decreases pain and opioid prescriptions, improves patient satisfaction, and decreases costs and utilization of healthcare services.

Logo for the IMPACt-LBP Demonstration Project

Learn more about IMPACt-LBP in this interview with investigators Christine Goertz, Adam Goode, and Rishi Chakraborty. The study was awarded continuation to the UH3 implementation phase last summer.

IMPACt-LBP is supported within the NIH Pragmatic Trials Collaboratory by the National Center for Complementary and Integrative Health, with additional support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Child Health and Human Development.